Patents Examined by Brian Gangle
  • Bacteria engineered to treat liver disease
    Patent number: 11439673
    Abstract: The disclosure provides genetically engineered bacteria that are capable of reducing excess ammonia and converting ammonia and/or nitrogen into alternate byproducts. The invention also provides pharmaceutical compositions comprising the genetically engineered bacteria, and methods of modulating and treating disorders associated with excess ammonia and inflammation in the gut and the liver, including, for example, hepatic encephalopathy, NASH/NAFLD, HCV, and Huntington's disease, in a subject, comprising administering the engineered bacterium to the subject.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: September 13, 2022
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Paul F. Miller, Vincent M. Isabella, Dean Falb, Jonathan W. Kotula, Yossi Dagon
  • Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
    Patent number: 11433086
    Abstract: Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, C—X—C Motif Chemokine Receptor 4 (CXCR4) receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: September 6, 2022
    Assignee: GlycoMimetics, Inc.
    Inventors: John L. Magnani, William E. Fogler
  • immune modulators and uses thereof
    Patent number: 11419901
    Abstract: A heat killed Porphyromonas gingivalis bacterium expressing a homogenous lipid A structure having a molecular negative mass ion of 1368, 1435/1449, or 1690/1768 is used as an immunomodulator. The immunomodulator may be used in combination with an antigen of interest to potentiate or restrain a host immune response toward the selected antigen.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: August 23, 2022
    Assignee: Trustees of Tufts College
    Inventors: Caroline Attaro Genco, George Papadopoulos
  • Method and system for reducing the likelihood of osteoporosis
    Patent number: 11419903
    Abstract: Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: August 23, 2022
    Assignee: SEED HEALTH, INC.
    Inventor: Joseph E. Kovarik
  • Methods and compositions for the treatment of C. difficile
    Patent number: 11419900
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: August 23, 2022
    Assignee: Artugen Therapeutics Ltd.
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel
  • Compositions and methods for immunizing against
    Patent number: 11419930
    Abstract: This disclosure relates to methods for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject. The subject may be at risk for a primary symptomatic C. difficile infection. In some embodiments, a method is for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject at risk for a primary symptomatic C. difficile infection, and comprises administering to the subject a composition comprising C. difficile toxoid A and toxoid B at least three times, each administration being about seven days apart.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: August 23, 2022
    Assignee: Sanofi Pasteur, Inc.
    Inventors: Patricia Pietrobon, Ginamarie Foglia, Guy De Bruyn, Sanjay Gurunathan
  • Capture purification processes for proteins expressed in a non-mammalian system
    Patent number: 11407784
    Abstract: Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed. Resin regeneration methods are also provided.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: August 9, 2022
    Assignee: Amgen Inc.
    Inventors: Joseph Edward Shultz, Roger Hart
  • Probiotic composition and feed additive
    Patent number: 11406672
    Abstract: Probiotic compositions containing a consortium of beneficial lactic acid fermenting microbes, bacteria belonging to the Bacilli family, and yeast are disclosed, and methods of using same as human probiotic for ingestion or as an animal feed additive are disclosed.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: August 9, 2022
    Assignee: SUSTAINABLE COMMUNITY DEVELOPMENT, LLC
    Inventors: Matthew T. Wood, Narin Tipsrisukond
  • Cytokine derived treatment with reduced vascular leak syndrome
    Patent number: 11401312
    Abstract: The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an interleukin 15 (IL-15) derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: August 2, 2022
    Assignees: Cytune Pharma, Institut Gustave Roussy (IGR)
    Inventors: David Bechard, Nathalie Chaput, Melanie Desbois
  • Method to reduce microbial bloom in poultry hatchery
    Patent number: 11395479
    Abstract: Spore forming bacteria and Lactic Acid Bacteria for application in poultry hatcher cabinets to alter the bacterial bloom towards a more beneficial microbiota, positively affecting performance parameters such as mortality, body weight gain and feed conversion ratio throughout production.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: July 26, 2022
    Assignees: Novozymes A/S, Board of Trustees of the University of Arkansas
    Inventors: Ross Wolfenden, Jacob Lum, Billy Hargis, Lisa Bielke, Lucas Graham
  • Stool collection method and sample preparation method for transplanting fecal microbiota
    Patent number: 11389488
    Abstract: The present invention relates to a method for preparing a homogeneous mixture of fecal microbiota from at least two preselected donors. The homogeneous mixture of fecal microbiota thus obtained has a bacterial diversity and an increased viability. The homogeneous mixture of fecal microbiota may be used for treating intestinal dysbiosis and for treating pathologies associated with such dysbiosis.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: July 19, 2022
    Assignee: MAAT PHARMA
    Inventors: Carole Schwintner, Alice Leroux, Clémence Mader, Hervé Affagard
  • Microbial consortia
    Patent number: 11369644
    Abstract: Provided herein are microbial strains isolated de novo. In some instances, the bacterial strains include genera, species, and/or strains of Lactobacillus johnsonii, Lactobacillus crispatus, Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium longum, and/or Bifidobacterium longum infantis strains. These bacterial strains can be used in the treatment of dysbiosis, inflammation, and other disorders.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: June 28, 2022
    Assignees: SIOLTA THERAPEUTICS, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Nikole Kimes, Ricardo Valladares, Benjamin Fiebiger, Susan V. Lynch
  • Vaccine to prevent mycoplasmal infections in waterfowl
    Patent number: 11369671
    Abstract: An improved vaccine for immunization of waterfowl such as ducks and geese comprises an inactivated strain of a mycoplasma infecting waterfowl, such as Mycoplasma sp. strain 1220; the vaccine can include an excipient and an adjuvant. Methods for immunization of waterfowl with the vaccine are also described.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: June 28, 2022
    Assignee: GalenBio, Inc.
    Inventors: Susan Szathmary, Laszlo Stipkovits
  • Inactivated and uses thereof for increasing physical performance
    Patent number: 11364268
    Abstract: The present subject matter provides, inter alia, compositions and methods comprising inactivated, non-viable, or dead Bacillus coagulans bacteria such as whole dead bacterial spores and/or cells and/or particles that comprise inactivated, non-viable, or dead Bacillus coagulans bacteria. Compositions and methods comprising Bacillus coagulans peptidoglycan and/or lipoteichoic acid are also provided.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: June 21, 2022
    Assignee: Ganeden Biotech, Inc.
    Inventors: David Keller, Howard Allen Cash, Sean Farmer
  • Compositions and methods for treating the eye
    Patent number: 11357805
    Abstract: The present invention relates to compositions comprising one or more compounds and/or extracts which induce, promote and/or improve production/release/delivery/excretion of mucin from and/or in the cornea, and methods of using the compositions to treat the eye.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: June 14, 2022
    Assignee: Johnson & Johnson Surgical Vision, Inc.
    Inventors: Wen-Hwa Ting Li, Khalid Mahmood, Ramine Parsa, Manpreet Randhawa, Mingqi Bai, Kenneth T. Holeva
  • Cell-based method for determining an activity of botulinum toxin
    Patent number: 11360081
    Abstract: A new cell line and an antibody for determining the activity of botulinum toxin are disclosed. Also disclosed is a method of determining the activity of botulinum toxin using the cell line and/or the antibody.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: June 14, 2022
    Assignee: HUGEL INC.
    Inventors: Chee Gun Lee, Ji Hyun Oum, Vijayakumar Ajay, Xiangai Gui
  • Anti-IL1-RAP antibodies
    Patent number: 11359025
    Abstract: Provided herein are antibodies specific for Interleukin-1 receptor accessory protein (IL1-RAP).
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: June 14, 2022
    Assignee: Cantargia AB
    Inventors: Ying Ping Jiang, Jagath R. Junutula, Leonard G. Presta
  • Anti-myostatin antibodies and methods of use
    Patent number: 11359009
    Abstract: The invention provides anti-myostatin antibodies and methods of using the same. In some embodiments, an isolated anti-myostatin antibody of the present invention binds to mature myostatin, and uptake of the antibody into cells is enhanced when complexed with the antigen. The invention also provides isolated nucleic acids encoding an anti-myostatin antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. Anti-myostatin antibodies of the present invention may be for use as a medicament. Anti-myostatin antibodies of the present invention may be for use in treating a muscle wasting disease. Anti-myostatin antibodies of the present invention may be for use in increasing mass of muscle tissue.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: June 14, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshinao Ruike, Taichi Kuramochi
  • Anti-nucleolin antibodies
    Patent number: 11357849
    Abstract: The present disclosure provides anti-nucleolin antibodies, methods of producing anti-nucleolin antibodies, and cells producing anti-nucleolin antibodies. Also provided are methods of using anti-nucleolin antibodies in treating malignant and non-malignant diseases.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: June 14, 2022
    Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Daniel Fernandes, Laura Schwartz, Natalie Sutkowski, Brian Hoel, Semyon Rubinchik
  • Method for diagnosis, prognosis or treatment of acute coronary syndrome (ACS) comprising measurement of plasma concentration of macrophage migration inhibitory factor (MIF)
    Patent number: 11360091
    Abstract: A method for diagnosing acute coronary syndrome (ACS) in a subject, the method comprising measuring plasma macrophage migration inhibitory factor (MIF) concentration in a sample from the subject, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, wherein the sample is taken less than 4 hours after symptom onset. The invention also relates to a method for prognosing ACS in a subject, the method comprising measuring plasma MIF concentration in a sample from the subject, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration. Also provided is a method of treating ACS in a subject, a device, a kit, and a cardiac biomarker related to the methods of diagnosing and prognosing ACS.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: June 14, 2022
    Assignees: ALFRED HEALTH, BAKER IDI HEART AND DIABETES INSTITUT HOLDINGS LTD.
    Inventor: Anthony Dart